Results from landmark M D Anderson CAR-NK clin... - CLL Support
Results from landmark M D Anderson CAR-NK clinical trial for B cell (CD19+) blood cancers
You need to be a member of this community to see this post.
Read more about...
23 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy
GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R) chronic lymphocytic leukemia...
An Early Look at When CAR-T Therapy Fails Patients With CLL
characteristics of patients with CLL who received anti-CD19 CAR-T therapy during a clinical trial...
flow cytometry is showing about 74% CLL involvement.
analyzed events. It dimly expresses the B-cell associated antigens CD19, CD20, CD22 and low...
CAR-T coming to OSU Medical Center
Clinical Trial monitoring I got the first tangible hints that CAR-T (Chimeric Antigen Receptor – T...
Diptheria Immunotoxin Effectively Targets B-Cell Malignancies - Phase 1 trial of DT2219
non-Hodgkin lymphoma whose tumors expressed CD19 and/or CD22. Eight patients had previously...
Richter Transformation - Update
48 months after last FCR Treatment!
Starting therapy 5 yrs post CAR-T with another immunotherapy trial, now epcoritamab
Immunotherapy and Gene Modification of T Cells
